It is important to differentiate whether isolated anti-HBc is due to false positive results or the prior exposure to hepatitis B virus, because individuals with false-positive anti-HBc can benefit from vaccination and their blood can be safely transfused. To distinguish between these two conditions, we evaluated the serologic response to hepatitis B vaccine.
INTRODUCTION
Chronic hepatitis B virus (HBV) infection is a potentially life-threatening liver disease with serious complications such as cirrhosis and hepatocellular carcinoma. Globally, more than 240 million people are infected with the virus. 1 The prevalence of HBV infection varies widely, with rates ranging from 0.1% to 20% worldwide. 2 Iran is an area of intermediate endemicity and the prevalence of chronic hepatitis B infection is reported to be 1.7% in general population. 3 Several serological markers are measured to distinguish hepatitis B infection status. It has been demonstrated that some HBs-Ag negative individuals with positive anti-HBc continue to replicate HBV. 4 Thus, the absence of HBs-Ag in the blood of apparently healthy individuals may not be sufficient to ensure an HBV-free status. Anti-HBc can be detected throughout the course of both acute and chronic HBV infection. It persists longlife after resolution, therefore the routine blood donor screening for anti-HBc has been implemented in some countries, resulting in a decrease in the risk of post-transfusion HBV infection. 5 In Iran, scanty reports dealing with isolated antiHBc screening are available. The reported rates range from 5.1% in Hamadan and 6.5% in Shiraz to as high as 34% in Sistan-Balouchestan. [6] [7] [8] Nevertheless, the associated figures for isoalted anti-HBc prevalnce in other studies were as low as 0.56% in the United Kingdom to as high as 76% in Ghana 9 However, most of previous studies reported isolated anti-HBc rates between 2-5%. 10, 11 Despite this fact, Iranian health policy makers have not introduced anti-HBc screening among blood donors, partly because of the lack of empirical data on the benefit of introducing anti-HBc screening in a donor population with low prevalence of HBV. On the other hand, the indefinite deferral of donors with falsepositive anti-HBc is a major disappointing side effect of anti-HBc screening in countries with low endemicity of HBV infection. 12 Therefore, anti-HBc screening of blood donations is still controversial.
It is of utmost importance to differentiate whether isolated anti-HBc is due to false positive results or the prior exposure to HBV, because individuals with false-positive anti-HBc can benefit from vaccination and their blood can be safely transfused.
To distinguish between the aforementioned conditions, evaluation of response to HB vaccination has been proposed. 13 In the present study, we investigated the antiHBs seroconversion in 2 groups of blood donors with isolated anti-HBc and their controls after HB vaccination. we also attempted to find the predictors of non-response status among individuals with isolated anti-HBc.
MATERIALS AND METHODS
This study was conducted in Zahedan Blood Transfusion Center. Ninety individuals with isolated anti-HBc positive test and 100 healthy persons with negative serological markers of hepatitis B were recruited in the study as case and control groups, respectively.
The exclusion criteria were: age > 64 years, previous HBV vaccination, organ transplantation, immunodeficiency disorders, hemodialysis, immunosuppressive therapy, contraindication for HBV vaccination (i.e. prior history of anaphylactic reaction to vaccine), positive results for HBs-Ag, antiHBs, anti-HCV, or anti-HIV tests and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels above 3 times normal cutoff values.
Also, none of the participants were positive for signs and symptoms of chronic hepatitis and cirrhosis. Prior to intervention, informed consents were obtained from all the participants, in accordance with the guidelines established by the Ethics Committee of Zahedan University of Medical Sciences.
All the participants were tested for HBV-DNA by qualitative polymerase chain reaction (PCR) (Cinna Gen Inc., Tehran, Iran) that could detect as low as 100 copy/mL of viral genome. we strictly adhered to the standard guideline of PCR procedure. The following reagents were added to each tube on ice: 1X PCR mixture 15 ul and Taq-DNA polymerase 0.4 ul. Then the tubes were shaken and spun thoroughly. The PCR mixture contained primers amplifying 353 bp of the region of the core gene. One drop (20-25 ul) of mineral oil was also added to each tube. Then, 10 ul DNA (with the use of specified pipette for sampling of DNA) was added to the mixture and spun on microfuge for 3-5 seconds. The tubes were transferred to preheated thermocycler with the following program: 1 cycle of 60 seconds at 93˚C, 20 seconds at 61˚C and 40 seconds at 72˚C, followed by 35 cycles of 93˚C, 61˚C, and 72˚C for 20, 20, and 40 seconds, respectively. Finally, 10 IU/mL of amplified samples were directly analyzed in a 2% agarose gel without adding loading buffer. The presence of 353 bp fragments indicated positive test. Afterwards, all subjects received three doses of 20 μg of hepatitis B recombinant vaccine (Heberbiovac HBR, Havana, Cuba) at 0, 1, and 6 months, if applicable (See below). The vaccine was injected intramuscularly into the deltoid muscle.
In order to quantify anti-HBs antibodies, a blood sample was taken 30 days after the first dose of the vaccine. Individuals with high titer anti-HBs response (anti-HBs > 50 mIU/mL) did not receive additional doses of the vaccine.
14,15 However, others completed the vaccination course, and another blood sample was collected 30 days after the third dose to measure anti-HBs level.
Anti-HBs titer ≥10 mIU/mL 30 days after the first vaccination was considered as early primary response. Also, late primary response was defined as anti-HBs titer ≥10 mIU/mL 30 days after the third dose of vaccines. Non-responders were individuals with <10 mIU/mL anti-HBs titers after receiving three doses of HB vaccine.
Statistical analysis:
Data were analyzed using SPSS for windows software, version 11.5 (SPSS Inc., Chicago, USA) and STATA version 9 (STATA Corp., College Station, Tex., USA). Fisher's exact test and Chisquared test were used as appropriate. Odd's ratios (ORs) were chosen to measure the association between dichotomous variables, and the results were adjusted for potential confounders by multivariate logistic modeling. Two-tailed significance tests were used in all statistical analyses. p values < 0.05 were considered as statistically significant.
RESULTS
The study population included 101 men and 89 women. Table 1 presents the demographic and important risk factors of the participants, comparing those with isolated anti-HBc to controls.
Participants of the case group were significantly older, and mostly married. The case group had also higher male/female ratio, and more history of transfusion and tattoo (p<0.05). However, history of infection in spouse, familial history of HBV infection, and serum AST and ALT levels was not significantly different between cases and controls.
Totally, 19 (21.1%) cases and 3 (3%) controls did not seroconvert (non-responder) after three doses of HB vaccine (p<0.0001). However, primary response was observed in 43 (47.8%) isolated anti-HBc positive cases and 92 (92%) controls (p<0.0001), of whom 15 cases and two controls seroconverted after the first dose of HB vaccine (early responder). Furthermore, anti-HBs titer ≥ 50 mIU/mL 30 days after the first dose of vaccine was significantly higher among cases (31.1% vs. 5%, p<0.0001). Two (2.2%) cases with positive isolated anti-HBc had detectable HBV DNA and were therefore, excluded from the analysis. Both of these two HBV DNA positive cases did not seroconvert after receiving 3 doses of vaccination. None of the cases and controls showed adverse effects after receiving recombinant HB vaccine. Table 2 compares non-responders (excluding 2 HBV DNA positive cases) with primary responders (including early and late responders). According to univariate analysis, serum anti-HBc positivity, age, and marital status were significantly different between the two groups; however, in multivariable analysis, only anti-HBc positivity and age remained independently associated with non-responding status. Indeed, anti-HBc positive subjects were 12.2 times (95% CI: 3.2-46.4, p<0.0001) more likely to fail seroconversion. Similarly, age ≥ 50 years was 3.6 times more likely to lead in non-responsive state (95% CI: 1.0-12.3, p<0.04). Also, anti-HBc positive participants were more likely to develop anti-HBs titer ≥ 50 mIU/mL 30 days after receiving the first dose of vaccine (table 3) .
As noted earlier, early response (anti-HBs titer ≥10 mIU/mL 30 days after the first vaccination) was found in 17 subjects. we compared early responders to late responders (the table is not included) and found a trend toward a higher seroprotective response rate after the first vaccination in the subjects with abnormal baseline ALT levels and those aged>50 years (ORs: 6.9 and 8, p<0.02 and p<0.001, respectively).
DISCUSSION
In our setting, we vaccinated isolated anti-HBc as well as healthy blood donors and monitored their response to HBV vaccination. A total of 19 (21.1%) cases and 3 (3%) controls did not seroconvert after receiving 3 doses of HB vaccine. Prior investigators reported a wide range of non-responding state, Sunbul 9.1%, 16 Coz yatacho 9.7%. 17 Pereira 10%, 18 Ural 10.4%, 19 Silva 20%, 13 Kabir 20.2% 20 and Koh 29.4%.
14 Therefore, at least 20% of isolated antiHBc positive cases may suffer from occult hepatitis B infection, for whom a diminished ability to mount an anti-HBs response is proposed.
Furthermore, in our study, anti-HBs titer ≥ 50 mIU/mL 30 days after the first dose of vaccine was developed in 28 (31.1%) cases and 5 (5%) controls. Scanty studies have addressed anamnestic rates; however, in a study reported by Sunbul and colleagues, 14 out of 33 (42.4%) subjects with isolated anti-HBc showed rapid high seroconversion, while in a report by Ural and co-workers, this rate was Abnormal 7 (7.7) 0 (0) 1) Abnormal level was defined as levels > 1.5 times upper than normal limit 2) NS: Not significant 3) Linear by linear association (chi-squared for linear trend); Exact method 41.7% (20 out of 48). 16, 19 Our lower rate could in part be explained by lower prevalence of HBV in our region. In such patients, further vaccination may not be necessary. Finally, 43 (47.8%) subjects with isolated positive anti-HBc and 92 (92%) controls showed primary response after the vaccination protocol. The associated figures were 48.4% and 47.9% in Sunbul and Ural study, respectively. 16, 19 Nevertheless, most of previous researchers assigned their subjects in two groups of responders (either primary or anamnestic) and non-responders. Accordingly, our cumulative responder rate would be 78.9% among subjects with isolated positive anti-HBc, which is in agreement with reports by Koh (70.6%), Kabir (79.8%), and Silva (80%), but lower than what reported by Ural (89.6%), Pereira (90%), yatacho (90.3%) and Sunbul (90.9%). 13, 14, [16] [17] [18] [19] [20] Discrepancies in response rate to HB vaccination among isolated anti-HBc subjects can be explained by serologic kit sensitivity, defining cut off points, and inclusion criteria for borderline results. Therefore, in our region, nearly 80% of isolated anti-HBc subjects can be safely included in the donor pool, simply based on a vaccination protocol. Notably, the isolated anti-HBc subjects with false positive results (47.8% in our setting) are susceptible to hepatitis B infection and should receive a complete course of HB vaccine. However, they may lose HB vaccination because of misinterpretation of antiHBc results.
On the other hand, our results revealed that individuals with isolated positive anti-HBc were significantly older, mostly married, had higher male/ female ratio, history of transfusion, tattoo and abnormal serum AST and ALT levels when compared with controls. The higher rate of anti-HBc positivity among older subjects mirrors a cohort effect of HBV infections acquired decades ago when HBV 1) Abnormal level was defined as levels > 1.5 times upper than normal limit 2) NS: Not significant 3) Linear by linear association (chi-squared for linear trend); Exact method. * participants with anti-HBs titer ≥ 50 mIU/mL 30 days after the first dose of vaccine and those with positive HBV DNA were excluded was moderately endemic in Iran and HBV National Vaccination Program had not been commenced. Furthermore, only two (2.2%) isolated anti-HBc positive cases had detectable HBV DNA. Recent studies suggest that 1-2% of anti-HBc reactive units contain low levels of HBV DNA. 21 However, in studies conducted on 4930 healthy blood donor volunteers in Fars and Hamadan provinces, 6.5% and 5.1% were isolated anti-HBc positive cases, among whom 16 (12.3%) and 3 (1.2%) were HBV DNA positive, respectively. 6, 7 Having compared non-responders to primary responders (table 2) , anti-HBc positivity, age, and marital status showed significant differences in univariable analysis. However, in multivariable analysis, only anti-HBc positivity and age (>50 years) remained independently associated with non-responding status. On the other hand, when we compared primary responders with those who developed anti-HBs titer ≥ 50 mIU/mL 30 days after the first dose of vaccine (table 3) , positivity for anti-HBc and age >50 years were the most relevant factors in developing higher anti-HBs titers to HBV vaccine. Therefore, isolated anti-HBc subjects aged >50 years would more likely either develop antiHBs titers ≥ 50 mIU/mL 30 days after receiving the first dose of vaccine or never respond to HB vaccine. As a result, one month after the first dose of 1) Abnormal level was defined as levels > 1.5 times upper than normal limit 2) NS: Not significant 3) Linear by linear association (chi-squared for linear trend); Exact method HB vaccine in isolated anti-HBc subjects aged >50 years, we can make a decision regarding whether to advise a strict follow-up (occult HBV infection) or assure the patient that he/she has a resolved HBV infection. Interestingly, when we compared the early and late responders (the table is not included), anti-HBc positivity, abnormal ALT level, and age >50 years were associated with a higher probability of early response. Therefore, anti-HBc positive subjects aged >50 years with abnormal ALT levels should be offered the first dose of HB vaccine and evaluated one month later in order to decide for their future follow-up. Various molecular modalities have been developed to determine if isolated anti-HBc subjects could transmit HBV infection. However, they will further increase the testing costs and require trained personnel and equipment, which may not be possible in many blood banks around the country. Thus, studying the cost effectiveness of 'monitoring the response to HB vaccination' could be worth of considering as a diagnostic tool. we also suggest future studies focusing on evaluating the short-course vaccination protocols such as double-dose/doubletime vaccination in order to make sooner decision.
In conclusion; using vaccination, we found that half of the subjects with isolated positive anti-HBc were falsely positive for the test and more than 75% of subjects with isolated positive anti-HBc could benefit from vaccination and could be included in donor pool. Moreover, one-fifth of subjects were non-responders and may have occult HBV infection. Because at least 5% of the donor population in Iran is anti-HBc positive, blindly rejecting antiHBc positive donors would cause the exclusion of a consistent number of donors, most of whom could safely be included in the donor pool. Therefore, HB vaccination may be used as a diagnostic tool for clarifying the situation of the subjects with isolated anti-HBc and can help in reducing the blood supply problems.
